Analysts Expect Fresenius Medical Care AG & Co. (FMS) to Post $0.44 Earnings Per Share

Analysts expect Fresenius Medical Care AG & Co. (NYSE:FMS) to post earnings per share of $0.44 for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Fresenius Medical Care AG & Co.’s earnings. The highest EPS estimate is $0.47 and the lowest is $0.42. Fresenius Medical Care AG & Co. reported earnings per share of $0.37 during the same quarter last year, which suggests a positive year-over-year growth rate of 18.9%. The company is scheduled to issue its next quarterly earnings report on Wednesday, May 3rd.

On average, analysts expect that Fresenius Medical Care AG & Co. will report full year earnings of $2.18 per share for the current fiscal year, with EPS estimates ranging from $2.11 to $2.25. For the next financial year, analysts forecast that the company will report earnings of $2.35 per share, with EPS estimates ranging from $2.24 to $2.40. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Fresenius Medical Care AG & Co..

Fresenius Medical Care AG & Co. (NYSE:FMS) last announced its earnings results on Wednesday, February 22nd. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.01. Fresenius Medical Care AG & Co. had a net margin of 6.67% and a return on equity of 10.56%. The firm earned $4.69 billion during the quarter, compared to the consensus estimate of $4.74 billion. During the same quarter in the previous year, the company posted $1.04 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis.



A number of equities research analysts have recently weighed in on FMS shares. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Sunday, March 12th. Zacks Investment Research raised Fresenius Medical Care AG & Co. from a “sell” rating to a “hold” rating in a research note on Friday, January 6th. Societe Generale downgraded Fresenius Medical Care AG & Co. from a “buy” rating to a “hold” rating in a research note on Friday, February 24th. Finally, DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, January 9th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $46.00.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) traded down 0.28% on Tuesday, reaching $42.72. 175,003 shares of the company traded hands. Fresenius Medical Care AG & Co. has a 52-week low of $38.05 and a 52-week high of $47.52. The company has a market capitalization of $26.16 billion, a PE ratio of 21.04 and a beta of 0.53. The firm has a 50-day moving average of $42.04 and a 200-day moving average of $41.18.

Several large investors have recently bought and sold shares of the company. Harding Loevner LP increased its stake in Fresenius Medical Care AG & Co. by 7.1% in the first quarter. Harding Loevner LP now owns 3,528,960 shares of the company’s stock worth $148,675,000 after buying an additional 233,347 shares during the period. Northern Trust Corp increased its stake in Fresenius Medical Care AG & Co. by 12.2% in the third quarter. Northern Trust Corp now owns 761,955 shares of the company’s stock worth $33,351,000 after buying an additional 83,125 shares during the period. Johnston Asset Management LLC increased its stake in Fresenius Medical Care AG & Co. by 4.4% in the third quarter. Johnston Asset Management LLC now owns 355,976 shares of the company’s stock worth $15,581,000 after buying an additional 14,890 shares during the period. Manning & Napier Advisors LLC increased its stake in Fresenius Medical Care AG & Co. by 9.2% in the third quarter. Manning & Napier Advisors LLC now owns 338,470 shares of the company’s stock worth $14,814,000 after buying an additional 28,410 shares during the period. Finally, Thornburg Investment Management Inc. purchased a new stake in Fresenius Medical Care AG & Co. during the fourth quarter worth $6,577,000. 2.52% of the stock is owned by institutional investors.

WARNING: “Analysts Expect Fresenius Medical Care AG & Co. (FMS) to Post $0.44 Earnings Per Share” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.themarketsdaily.com/2017/04/21/analysts-expect-fresenius-medical-care-ag-co-fms-to-post-0-44-earnings-per-share.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

5 Day Chart for NYSE:FMS

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply